TD2 Oncology and Curadh Form Strategic Partnership to Accelerate Radiopharmaceutical Development for Solid Tumors
核心洞察
TD2 Oncology (搜索), a global oncology CRO, has entered a strategic collaboration with Curadh MTR (搜索) to advance molecularly targeted radiopharmaceutical therapies (搜索) for difficult-to-treat solid tumors (搜索).
The partnership combines TD2's clinical trial execution expertise with Curadh's radiopharmaceutical innovation to address complex development challenges including specialized logistics and multi-jurisdictional regulations.
Curadh is founded by Dr. Alison Armour, who previously led the clinical development of PSMA617 for Endocyte (搜索), which was later approved as Pluvicto®, currently the world's leading radiopharmaceutical drug.
TD2 Oncology (搜索), a global full-service oncology contract research organization, has announced a strategic collaboration with Curadh MTR (搜索), Inc., a biotechnology company pioneering molecularly targeted radiopharmaceutical therapies (搜索) for solid tumors (搜索). The partnership aims to accelerate the development of next-generation targeted therapies for patients with difficult-to-treat cancers by combining TD2's proven oncology execution capabilities with Curadh's scientific innovation in the radiopharmaceutical space.
Addressing Complex Development Challenges
Radiopharmaceuticals (搜索) deliver radiation directly to cancer (搜索) cells, offering transformative potential across multiple tumor types. However, clinical development in this space remains complex, requiring specialized logistics, isotope handling, and navigating multi-jurisdictional regulations. The global radiopharmaceuticals market approaches USD 7.51 billion and continues to grow, presenting significant opportunities for innovative therapeutic approaches.
TD2 and Curadh will jointly address these challenges using an integrated clinical development model that spans regulatory strategy through early-phase execution. This comprehensive approach is designed to overcome the unique obstacles that have historically slowed radiopharmaceutical development.
Leadership Perspectives on the Partnership
"This collaboration marks the beginning of a powerful partnership between two organizations dedicated to advancing precision oncology," said Steve Gately, PhD, Chief Executive Officer of TD2. "As radiopharmaceuticals (搜索) continue to emerge as a powerful modality in cancer (搜索) care, we're proud to contribute our clinical trial execution capabilities to accelerate these promising therapies and help expand access to patients globally."
Glenn Kazo, Chief Executive Officer of Curadh, emphasized the strategic value of the partnership: "TD2's proven track record in complete oncology trials makes them the ideal partner as we bring our radiopharmaceutical programs into clinical development. This collaboration strengthens our abilities to navigate the unique challenges of MTR trials and positions us to deliver meaningful innovations for patients who urgently need new treatment options."
Company Backgrounds and Expertise
TD2 Oncology (搜索) was founded by Dr. Dan Von Hoff in 2003 and operates as a full-service global oncology contract research organization with deep expertise in complex oncology trials across a broad range of drug classes, including radiopharmaceuticals (搜索). The company is dedicated to advancing oncology drug development with exceptional scientific insight, operational efficiency, and strategic execution.
Curadh MTR (搜索), Inc. is dedicated to advancing second-generation radiopharmaceuticals (搜索) through innovative drug design and strategic partnerships combining novel targets and new radioisotopes. The company was founded by Dr. Alison Armour, who led the clinical development of PSMA617 for Endocyte (搜索), later approved as Pluvicto®, the world's leading radiopharmaceutical drug. Curadh is headed by an expert team in MTR development.
Future Outlook
The TD2–Curadh collaboration reflects a shared commitment to tackling some of the most complex challenges in oncology drug development. By combining operational strength and scientific innovation, both organizations aim to accelerate the delivery of radiopharmaceutical therapies that could redefine treatment paradigms for patients with difficult-to-treat cancers. Additional updates on program milestones and trial progress are expected in the coming months.